Biolidics Overview
- Founded
-
2009
- Status
-
Public
- Employees
-
26
- Stock Symbol
-
8YY
- Investments
-
1
- Share Price
-
$0.01
- (As of Friday Closing)
Biolidics General Information
Description
Biolidics Ltd is engaged in research, experimental development, marketing, and distribution of biotechnology, life and medical science and electronics related industrial design services and investment holding. Its segments include Cancer; Infectious diseases; and Laboratory services. It derives major revenue from the infectious diseases segment that involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field. Its operations are spread across Singapore, Japan, China, Europe, United States, Hong Kong, Philippines, Indonesia, and Others.
Contact Information
Website
www.biolidics.com
Formerly Known As
Clearbridge BioMedics
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Stock Exchange
SES
Primary Office
- 37 Jalan Pemimpin
- Number 02-07
- Mapex, 577177
- Singapore
Biolidics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.01 | $0.01 - $0.09 | $6.28M | 522M | 4.98M | -$0.01 |
Biolidics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 7,052 | 35,144 | 56,205 | 37,434 |
| Revenue | 1,501 | 1,722 | 6,456 | 1,054 |
| EBITDA | (2,561) | (3,409) | (2,600) | (3,135) |
| Net Income | (3,587) | (4,453) | (3,371) | (3,525) |
| Total Assets | 4,939 | 8,448 | 14,175 | 7,136 |
| Total Debt | 2,298 | 3,142 | 3,987 | 398 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biolidics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biolidics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Biolidics Ltd is engaged in research, experimental development, marketing, and distribution of biotechnology, life and m
Biotechnology
Mapex, Singapore
26
As of 2018
000.00
000000000
000.00
000000
ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
000000000 00000 (000
San Francisco, CA
000
As of 0000
00000
000000000
00000
00000
elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
000000000000000
Ahmedabad, India
00000
As of 0000
000.00
0.00
0000-00-00
00000000000
000.00
Add Comparison
Biolidics Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Standard BioTools | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000000 | 00000 |
| 00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Corporation | Mumbai, India | 00000 | 00000 | 000000000 | 00000 |
Biolidics Patents
Biolidics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6924210-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
| US-11059042-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
| AU-2016405636-A1 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
| AU-2016405636-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
| EP-3455337-A4 | Systems and methods for enriching target cells in a sample | Pending | 04-May-2016 | B01L3/502761 | 0 |
Biolidics Executive Team (13)
Biolidics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Beng Kwan Chia | Biolidics | Board Member | 000 0000 |
| Jeremy Yee | Self | Co-Chief Executive Officer & Non-Executive Non-Independent Chairman | 000 0000 |
| Johnson Chen | Self | Board Member & Founder | 000 0000 |
| Tony Qian | Biolidics | Board Member | 000 0000 |
Biolidics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Biolidics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biolidics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 000 | 26-May-2020 | 0000000000 | 00.000 | Laboratory Services (Healthcare) |
Biolidics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000000000 00000000 | Laboratory Services (Healthcare) | Singapore, Singapore | 0000 |
Biolidics ESG
Risk Overview
Risk Rating
Updated February, 21, 2023
35.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Healthcare
Industry
00 of 601
Rank
00.00
Percentile
Medical Devices
Subindustry
00 of 207
Rank
00.00
Percentile
